SEC Form 4 · accession 0001654954-18-010575
Monopar Therapeutics · MNPR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher M Starr
Director
Period of report
Aug 9, 2018
Accepted (ET)
Sep 27, 2018 · 6:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645469
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF1 | holding | — | — | — | 49,400 | I | See Footnote (1) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock optionsF2 | $6.00 | Aug 9, 2018 | A | 26,100 | A | Jan 1, 2019 | Aug 8, 2028 | Common stock | 26,100 | 26,100 | D |
Explanation of responses
- F149,400 shares of Monopar Common Stock held by the Christopher M. Starr and Sheri L. Starr Revocable Trust over which Dr. Starr serves as Trustee.
- F2Stock options vest 20% on January 1, 2019, 20% on April 1, 2019, 20% on July 1, 2019, 20% on October 1, 2019 and 20% on January 1, 2020.